150 related articles for article (PubMed ID: 38272454)
21. Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression.
Shi Q; Yu J; Liu D; Ren F; Wu J; Shen K
BMC Cancer; 2023 Feb; 23(1):173. PubMed ID: 36810001
[TBL] [Abstract][Full Text] [Related]
22. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
[TBL] [Abstract][Full Text] [Related]
23. Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer.
Gaudio M; Jacobs F; Benvenuti C; Saltalamacchia G; Gerosa R; De Sanctis R; Santoro A; Zambelli A
Breast Cancer Res Treat; 2024 Feb; 203(3):487-495. PubMed ID: 37923964
[TBL] [Abstract][Full Text] [Related]
24. HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications.
Tarantino P; Niman SM; Erick TK; Priedigkeit N; Harrison BT; Giordano A; Nakhlis F; Bellon JR; Parker T; Strauss S; Jin Q; King TA; Overmoyer BA; Curigliano G; Regan MM; Tolaney SM; Lynce F
Eur J Cancer; 2022 Oct; 174():277-286. PubMed ID: 36116830
[TBL] [Abstract][Full Text] [Related]
25. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China.
Dai Q; Feng K; Liu G; Cheng H; Tong X; Wang X; Feng L; Wang Y
Target Oncol; 2024 Jan; 19(1):81-93. PubMed ID: 38265547
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological features and prognosis of patients with HER2-low breast cancer.
Yang X; Li Y; Lu X; Ren X; Hua B
BMC Cancer; 2023 Sep; 23(1):914. PubMed ID: 37770874
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience.
Xu H; Han Y; Wu Y; Wang Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Ma F; Xu B; Wang J
Front Oncol; 2022; 12():906011. PubMed ID: 35785207
[TBL] [Abstract][Full Text] [Related]
29. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
31. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
[TBL] [Abstract][Full Text] [Related]
32. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
[TBL] [Abstract][Full Text] [Related]
33. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
[TBL] [Abstract][Full Text] [Related]
34. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients.
Chen Z; Jia H; Zhang H; Chen L; Zhao P; Zhao J; Fu G; Xing X; Li Y; Wang C
Breast Cancer Res Treat; 2023 Nov; 202(2):313-323. PubMed ID: 37639064
[TBL] [Abstract][Full Text] [Related]
35. A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer.
Lee SB; Sohn G; Kim J; Chung IY; Lee JW; Kim HJ; Ko BS; Son BH; Ahn SH
Breast Cancer Res Treat; 2018 Jun; 169(2):257-266. PubMed ID: 29388016
[TBL] [Abstract][Full Text] [Related]
36. [HER2 expression and its prognostic implication in lymph node negative breast carcinoma: a Meta-analysis].
Guo H; Wei B; Zhang HY; Liu GJ; Bu H; Lang ZQ; Tang X; Dai QQ; Chen HJ; Zhou Y
Zhonghua Bing Li Xue Za Zhi; 2005 Mar; 34(3):140-6. PubMed ID: 15938823
[TBL] [Abstract][Full Text] [Related]
37. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
[TBL] [Abstract][Full Text] [Related]
38. Survival differences between HER2-0 and HER2-low-expressing breast cancer - A meta-analysis of early breast cancer patients.
Yang C; Zhang X; Chen Y; Li P; Zhang J; Xu A; Huang N; Liang M; Chen Y; Wang K
Crit Rev Oncol Hematol; 2023 May; 185():103962. PubMed ID: 36921780
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathological features and prognosis of HER2-negative luminal-type breast cancer patients with early and late recurrence].
Chen XL; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):448-53. PubMed ID: 27346403
[TBL] [Abstract][Full Text] [Related]
40. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
